UMass Medical School signs investigational drug agreement for rare diseases
Photo | Google
The MassBiologics facility in Fall River
A biotechnology arm of the UMass Medical School has signed an agreement with a New Jersey pharmaceutical company to make investigational new drugs and commercial pharmaceutical products.
The agreement, which the Worcester school announced Tuesday, will help PTC Therapeutics create new medicines for rare diseases.
MassBiologics, part of UMass Medical School, will provide dedicated manufacturing and quality control teams at its laboratory in Fall River and manufacture an investigational therapy for a rare genetic condition. The condition, known as AADC deficiency, is caused by the absence of a functioning enzyme that causes developmental delays or failures, including milestones with head control, standing, walking or talking.
The condition can also include seizure-like episodes and require life-long care, the medical school said.
Financial terms were not disclosed. PTC Therapeutics has sites worldwide, including an office in Lynnfield.
WBJ Web Partners
Most Recent
Most Recent
0 Comments